StockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report issued on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

NASDAQ BLPH opened at $0.04 on Thursday. The company has a market cap of $428,155.00, a PE ratio of -0.04 and a beta of 0.73. The firm’s 50 day moving average price is $0.04 and its 200-day moving average price is $0.05. Bellerophon Therapeutics has a 52-week low of $0.03 and a 52-week high of $0.46.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.